Walden Group Healthcare M&A Blog

  • Walden Advises Halma plc (LSE:HLMA) in its acquisition of Visiometrics, S.L. (Barcelona, Spain)

    12/19/2015
    The Walden Group is pleased to announce that it has advised Halma plc, a UK-based public company, in its acquisition of Visiometrics, S.L., located outside Barcelona, Spain. On Halma's behalf, The Walden Group identified Visiometrics as a strategic fit, cultivated a relationship with Visiometrics' principals, advised Halma on the transaction, and...
    Read More
  • Medtronic's 2015 Deal Appetite Whetted By Tax Savings

    10/27/2015
    Medtronic's most recent acquistion target was Lazarus Effect, a maker of stroke diagnostic devices. After obtaining European approval, Lazarus Effect is working to get U.S. approval for the ReCover brain blot clot removal device, which works with Medtronic 's Solitaire stent that can be deployed in the brain to scoop out vessel-blocking clots that...
    Read More
  • VasSol Ushers in a New Stroke Diagnostic Standard of Care

    10/07/2015
    The Journal of the American Medical Association - Neurology (JAMA Neurology) has indicated it will publish the results of the landmark stroke diagnostic study - VERiTAS (Vertebrobasilar Flow Evaluation and Risk of Transient Ischaemic Attack and Stroke study (VERiTAS).  Acceptance by this highly prestigious and influential peer-reviewed journal...
    Read More
  • Aesthetic Surgery Market Trends - 2015

    09/29/2015
    Key factors "shaping" the aesthetic surgery market and healthcare M&A activity in it are: Large and Growing Market 15.6 million cosmetic procedures, including both minimally-invasive and surgical, were performed in the US in 2014, an increase of 3% since 2013. Additionally, 5.8 million reconstructive surgery procedures were performed last...
    Read More
  • Allergan buys AqueSys, a maker of minimally invasive glaucoma surgery products, for $300m+

    09/17/2015
    The deal provides Allergan with AqueSys's minimally invasive glaucoma surgery (MIGS) device called the XEN45 Gel Stent.  MIGS devices are alternatives to glaucoma medication and more invasive surgical techniques.  The leader in the MIGS area is Glaukos, which closed an IPO in June 2015 and now has a market cap of over $1b.  Its iStent is...
    Read More
  • Page 10 of 13« First...89101112...Last »